ArticleEuropean radiology2025
Node-RADS category on preoperative CT predicts prognosis in patients with papillary renal cell carcinoma.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- CT-based Node-RADS for evaluating regional lymph node metastasis and postoperative recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfront surgery.European radiology · 2026Article
- Assessment of inter-reader agreement and diagnostic performance of Node-RADS in colon cancer.Insights into imaging · 2026Article
- Prognostic and Diagnostic Value of Node-RADS for Non-Small Cell Lung Cancer Following Neoadjuvant Therapy: A Multicenter Cohort Study.Diagnostics (Basel, Switzerland) · 2026Article
- Prognostic value of pretherapy CT-based Node-RADS for overall survival in extensive-stage small cell lung cancer treated with chemoimmunotherapy: a comparison with clinical N staging.Quantitative imaging in medicine and surgery · 2026Article
- A preoperative CT-based radiological score for predicting recurrence in papillary renal cell carcinoma: a multicenter validation study.Insights into imaging · 2025Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
objectivesThis research focused on investigating the relationship between the Node Reporting and Data System (Node-RADS) categories, determined via preoperative CT, and the outcomes of progression-free survival (PFS) and cancer-specific survival (CSS) in individuals diagnosed with papillary renal cell carcinoma (pRCC).
methodsA retrospective multicenter study initially enrolled 454 patients, with 218 eligible for analysis following partial nephrectomy or radical resection for pRCC. Prognostic factors related to PFS and CSS in pRCC patients were identified through univariate and multivariate Cox regression analyses. Subsequently, the prognostic value of Node-RADS was assessed and compared with the existing pRCC risk stratification model.
resultsIn total, 218 patients (mean age, 58 years; men, 164 [75.2%]) with pRCC (186 Node-rads I tumors (85.3%), 10 Node-rads II tumors (4.6%), and 22 Node-rads III tumors (10.1%)) were included. The Node-RADS category emerged as an independent prognostic factor for PFS (III vs II vs I, hazard ratio (HR) 4.250, p < 0.001) and CSS (III vs II vs I, HR 4.466; p < 0.001). When the Node-RADS category was incorporated into Leibovich's model, the resulting combined model demonstrated a significant improvement in predictive accuracy (C-index: 0.865 versus 0.755, p = 0.005 for PFS; and 0.921 versus 0.835, p = 0.01 for CSS).
conclusionThe Node-RADS category has been identified as a more accurate predictor of prognosis for pRCC, regardless of pathologic lymph node involvement. These findings need further confirmation in prospective studies. KEY POINTS: Question Lymph node status is important for papillary renal cell carcinoma prognosis, and there is a lack of consensus on radiological evaluation. Findings Node-RADS is an independent predictor of progression-free survival and cancer-specific survival in papillary renal cell carcinoma. Clinical relevance The Node Reporting and Data System category improves the accuracy of the Leibovich model for prognosis, which can help clinical practitioners select individualized treatment plans for each patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.